Navigation Links
Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Date:9/6/2007

is of safety and efficacy to be conducted based on predefined criteria. Kosan anticipates providing more information on the TIME-1 trial design upon initiation.

The TIME-2 clinical trial is being conducted at clinical sites primarily in the US and in Europe and is designed to enroll approximately 130 patients with relapsed-refractory multiple myeloma. The trial is designed to test three different doses of tanespimycin in combination with the approved dose and schedule of bortezomib (Velcade(R)) (1.3 mg/m2). The tanespimycin dose groups are 50 mg/m2, 175 mg/m2 and 340 mg/m2. Tanespimycin will be administered twice weekly as a one-hour intravenous infusion on a cycle of two weeks of treatment every three weeks (the same schedule as bortezomib). Patients eligible to participate in the TIME-2 trial must have been treated with and progressed following at least three prior treatments for multiple myeloma. Prior regimens must include bortezomib and lenalidomide (Revlimid(R)). The primary endpoint of the trial is the dose response based on objective response rate after 4 cycles of treatment. Secondary endpoints include a comparison of response rate between the three dose groups, progression-free survival, time to treatment failure and overall survival. Objective response rate in multiple myeloma is measured primarily by the patient's level of M protein.

About the Special Protocol Assessment

As stated in the Prescription Drug User Fee Act (PDUFA) and FDA's Guidance for Industry Special Protocol Assessment, "...having agreed to the design, execution, and analyses proposed in protocols reviewed under this process ... the Agency will not later alter its perspective on the issues of design, execution, or analyses unless public health concerns unrecognized at the time of protocol assessment under this process are evident. Thus, documented special protocol assessments should be considered binding on the review division and should not be changed at any time..." as
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
9. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
10. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
11. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015  Today, in final recognition ... Contact Lens Health Week, 1-800 Contacts is sharing how ... that contact lens wearers who do not properly care ... for eye infections. Most contact lens ... but a clean lens case is sometimes overlooked.  When ...
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on China,s ... Developed by Novartis, ranibizumab was approved by CFDA ... 2012. Currently, only Lucentis, a product of Novartis, is ... as the first self- developed drug for the treatment ...
(Date:8/28/2015)... Denmark and ATLANTA , August ... the US Food and Drug Administration (FDA) cleared the MagVita ... in adult patients who have failed to receive satisfactory improvement ... a non-invasive technique for stimulating neural tissue in the part ... Disorder. The procedure has been proven safe and effective and ...
Breaking Medicine Technology:1-800 Contacts Shares Tips on How to Clean Lens Cases 2Investigation Report on China's Ranibizumab Market, 2012-2019 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3
... 23, 2011 A recently enacted standard has replaced ...  This superseding standard, the Statement on Standards for Attestation ... 15, 2011 and pushes service organizations to enforce a ... (Logo: http://photos.prnewswire.com/prnh/20080206/AQW030LOGO-b ) Rising ...
... 23, 2011 Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... presenting at the Jefferies 2011 Global Healthcare Conference in ... Officer of Unilife, is scheduled to present at 5:00 ... Wednesday, September 28, 2011. The conference presentation ...
Cached Medicine Technology:Rising Medical Solutions, an Early Adopter of SAS 70's Replacement Standard 2Rising Medical Solutions, an Early Adopter of SAS 70's Replacement Standard 3Unilife to Present at the Jefferies 2011 Global Healthcare Conference in London 2
(Date:8/29/2015)... , ... August 29, 2015 , ... ProDrop Particles includes ... Each preset contains 15 seconds of unique footage that users can shrink and stretch ... zoom, attract and more. Users can customize color, brightness, scale, speed, range, and flare ...
(Date:8/29/2015)... ... 29, 2015 , ... The popular television program VOICES IN AMERICA, hosted by ... will be devoting an entire short segment to the subject of diabetes. Diabetes is ... on a daily basis, but recent advancements in medical science may prove to be ...
(Date:8/28/2015)... ... August 28, 2015 , ... Joining ... County Memorial Hospital recently transitioned management companies to partner with Wound Care Advantage ... their outpatient wound center. , Transitioning wound care management providers can be ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of Workforce Investment Commissioner ... they are applying for, they are unable to pass the initial drug test and ... testing policies in order to be able to hire long-term, skilled talent. (1) Will ...
(Date:8/28/2015)... ... August 28, 2015 , ... For Dallas, the time is nearing ... their subsidiary USPI Tenet Health. , The American Heart Association hosts their well-known Heart ... They believe that together, a difference can be made. Walkers can participate in the ...
Breaking Medicine News(10 mins):Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2
... Award-winning car toys offer schools innovative teaching tool ... RANDOLPH, Mass., July 20 May Institute, the National Autism ... for Classrooms," a unique summer charitable campaign created to donate innovative ... Automoblox, the retro-modern, mix-and-match car design system, has won major awards ...
... , Teamsters File Charge ... Waste into Open Refuse Dumpsters , , ... the Environmental Investigations Division of the City of St. Louis today charging American ... , The complaint was filed after red biohazard bags ...
... , Statement by ... Homecare , , ARLINGTON, Va., ... healthcare system, the Obama administration and Members of Congress have been ... provides medical oxygen, respiratory therapy, hospital beds, wheelchairs, walkers and other ...
... , , , , ... a higher risk for heart disease, stroke, and ... percent of the U.S. population is living without dental insurance - nearly ... , To help make dental care more accessible to people, ...
... H1N1 swine flu vaccine, which should be ready by fall ... and Drug Administration has approved the vaccine to protect against ... agency noted that this vaccine will not protect people from ... around the world and is expected to return to the ...
... in processed foods, experts advise reading food labels , MONDAY, ... diet contribute to hypertension, but it can also reduce the ... "What is striking about these results is the degree of ... medicine at the University of Alabama at Birmingham, and a ...
Cached Medicine News:Health News:May Institute, National Autism Center, and Automoblox Launch 'Cars for Classrooms' Summer Charitable Campaign to Benefit Children with Autism 2Health News:May Institute, National Autism Center, and Automoblox Launch 'Cars for Classrooms' Summer Charitable Campaign to Benefit Children with Autism 3Health News:May Institute, National Autism Center, and Automoblox Launch 'Cars for Classrooms' Summer Charitable Campaign to Benefit Children with Autism 4Health News:Congress Must Recognize Homecare as Cost-Effective Part of Health Care Reform 2Health News:Congress Must Recognize Homecare as Cost-Effective Part of Health Care Reform 3Health News:More Americans Have Cell Phones Than Dental Coverage 2Health News:FDA Approves Seasonal Flu Vaccine for 2009-2010 2Health News:FDA Approves Seasonal Flu Vaccine for 2009-2010 3Health News:High-Salt Diet Dampens Effects of Blood Pressure Drugs 2Health News:High-Salt Diet Dampens Effects of Blood Pressure Drugs 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: